Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling

Go back to Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling
(NASDAQ: KLRS) Delayed: 3.20 +0.04 (1.27%)
Previous Close $3.16    52 Week High
Open $3.18    52 Week Low
Day High $3.23    P/E N/A 
Day Low $3.04    EPS
Volume 234,397